Visgenx: Taking retinal gene therapy beyond rare disease

Visgenx is delivering a gene therapy to restore expression of an enzyme involved in a fatty acid pathway that the company believes could slow or stop progressive vision loss in patients with age-related macular degeneration.

The strategy represents a departure from the more common use of gene therapy — to deliver a functional copy of a gene that’s mutated in a rare and severe genetic disorder. ...